デフォルト表紙
市場調査レポート
商品コード
1611045

米国の自己免疫疾患用IVDとLDT市場規模、シェア、動向分析レポート:タイプ別、技術別、用途別、セグメント別予測、2025~2030年

U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type, By Technology (Immunoassays, Clinical Chemistry, Molecular Diagnostics), By Application (Psoriasis, Crohn's Disease), And Segment Forecasts, 2025 - 2030


出版日
ページ情報
英文 110 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.69円
米国の自己免疫疾患用IVDとLDT市場規模、シェア、動向分析レポート:タイプ別、技術別、用途別、セグメント別予測、2025~2030年
出版日: 2024年11月19日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の自己免疫疾患用IVDとLDT市場の成長と動向

Grand View Research, Inc.の最新レポートによると、米国の自己免疫疾患用IVDとLDT市場規模は2030年までに38億8,000万米ドルに達し、2025~2030年のCAGRは6.6%で成長すると予測されています。

自己免疫疾患の有病率の高さ、これらの病気に対する意識の高まり、技術開発された高性能製品に対する需要の高まり、研究開発への高額投資が市場成長の拡大要因となっています。

これらの健康問題は、米国における慢性疾患の第二の原因であり、米国女性の主要な死因の一つです。これらの疾患は、患者の労働生産性や生活の質に悪影響を及ぼし、米国の医療費支出に大きな影響を与える経済的負担となっています。National Institute of Healthラボは、これらの疾患に関連する直接的な医療費は約1,000億米ドルで、がんの医療費は570億米ドルに上ると推定しています。

これらの疾患を患う人々の多さと、米国における医療費の増加をもたらす驚くべき速度での有病率の上昇は、すべて優先事項であり、したがって、成長を促進することが期待されています。さらに、内臓の損傷、運動能力の低下、死亡の危険性など、このような健康障害に起因する合併症は、このような状態の早期診断と介入を極めて重要なものにしています。このような状態に対する意識の高まりが市場成長を牽引すると予想されます。

世界の自己免疫疾患の増加は、遺伝的素因と環境要因によるものだと多くの研究者が考えています。しかし、環境中の何が自己免疫疾患の発生を引き起すのかについての知識はほとんどないです。

FDAは体外診断用医薬品を医療機器として規制しているが、過去にはLDTを規制する権限はありません。その後、FDAはLDTを規制するために医療機器規制の権限を行使すると発表しました。LDTに対するFDAの規制は、検査開発に必要な時間とコストの増加につながると考える研究者もいます。

米国の自己免疫疾患向けIVDとLDT市場レポートハイライト

  • IVDセグメントは2024年に大きな市場シェアを獲得し、予測期間にはCAGR 6.26%で成長する見込みです。
  • 乾癬は2024年に15.21%の最大シェアを占め、予測期間を通じて支配的なシェアを維持すると予想されます。乾癬の有病率の上昇と、診断精度を向上させるためにNPFが行った戦略的イニシアチブは、同セグメントの成長に寄与する主要要因です。
  • 臨床化学セグメントは、2024年に30.32%の最大の収益シェアを占めました。臨床化学検査は、患者の様々な疾患の検査と診断において中心的な役割を果たしています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • SWOT分析(要因別)
  • 産業分析-ポーターのファイブフォース分析
  • 消費者行動分析
  • 対象疾患集団
  • 規制シナリオ
  • 償還シナリオ
  • アンメットニーズと機会の分析

第4章 タイプビジネス分析

  • 米国の自己免疫疾患向けIVDとLDT市場:タイプ変動分析
  • 体外診断
    • IVD市場、2018~2030年
    • 技術別
    • 用途別
  • LDDT
    • LDT市場、2018~2030年
    • 技術別
    • 用途別

第5章 技術ビジネス分析

  • 米国の自己免疫疾患向けIVDとLDT市場:技術変動分析
  • 免疫アッセイ
    • 免疫アッセイ市場、2018~2030年
  • 臨床化学
    • 臨床化学市場、2018~2030年
  • 血液学
    • 血液学市場、2018~2030年
  • 凝固
    • 凝固市場、2018~2030年
  • 微生物学
    • 微生物学市場、2018~2030年
  • 分子診断
    • 分子診断市場、2018~2030年
  • その他
    • その他市場、2018~2030年

第6章 用途ビジネス分析

  • 米国の自己免疫疾患向けIVDとLDT市場:用途変動分析
  • アジソン病
    • アジソン病市場、2018~2030年
  • 強直性脊椎炎
    • 強直性脊椎炎市場、2018~2030年
  • 円形脱毛症
    • 円形脱毛症市場、2018~2030年
  • 関節リウマチ
    • 関節リウマチ市場、2018~2030年
  • 全身性エリテマトーデス
    • 全身性エリテマトーデス市場、2018~2030年
  • 全身性強皮症
    • 全身性硬化症市場、2018~2030年
  • 乾癬
    • 乾癬市場、2018~2030年
  • 抗リン脂質抗体症候群
    • 抗リン脂質抗体症候群市場、2018~2030年
  • 1型糖尿病
    • 1型糖尿病市場、2018~2030年
  • クローン病
    • クローン病市場、2018~2030年
  • 潰瘍性大腸炎
    • 潰瘍性大腸炎市場、2018~2030年
  • ナルコレプシー
    • ナルコレプシー市場、2018~2030年
  • 多発性硬化症
    • 多発性硬化症市場、2018~2030年
  • ぶどう膜炎
    • ぶどう膜炎市場、2018~2030年
  • その他
    • その他市場、2018~2030年

第7章 競合情勢

  • 企業分類
  • 戦略マッピング
    • 新製品発売
    • パートナーシップとコラボレーション
    • 合併と買収
    • その他
  • 企業市場シェア分析、2024年
  • 企業プロファイル/上場企業
    • Adaptive BIoTechnologies Corporation
    • Agilent Technologies, Inc
    • Bio-Rad Laboratories, Inc.
    • bioMerieux, Inc.
    • Corgenix, Inc.(Sebia)
    • F. Hoffmann-La Roche Ltd.
    • Quest Diagnostics, Inc.
    • PerkinElmer, Inc
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by type, 2018 - 2030 (USD million)
  • Table 4 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by application, 2018 - 2030 (USD million)
  • Table 5 U.S. IVD & LDT for autoimmune diseases market revenue estimated and forecast, by technology, 2018 - 2030 (USD million)
  • Table 6 Company market share, 2024

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. IVD & LDT For Autoimmune Diseases Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 U.S. IVD & LDT For Autoimmune Diseases Market: Type outlook and key takeaways
  • Fig. 15 U.S. IVD & LDT For Autoimmune Diseases Market: Type movement analysis & market share 2024 & 2030
  • Fig. 16 IVD market, 2018 - 2030 (USD Million)
  • Fig. 17 LDT market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. IVD & LDT For Autoimmune Diseases Market: Technology outlook and key takeaways
  • Fig. 19 U.S. IVD & LDT For Autoimmune Diseases Market: Technology movement analysis & market share 2024 & 2030
  • Fig. 20 Immunoassays market, 2018 - 2030 (USD Million)
  • Fig. 21 Clinical Chemistry market, 2018 - 2030 (USD Million)
  • Fig. 22 Hematology market, 2018 - 2030 (USD Million)
  • Fig. 23 Coagulation market, 2018 - 2030 (USD Million)
  • Fig. 24 Microbiology market, 2018 - 2030 (USD Million)
  • Fig. 25 Molecular Diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 26 Others market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. IVD & LDT For Autoimmune Diseases Market: Application outlook and key takeaways
  • Fig. 28 U.S. IVD & LDT For Autoimmune Diseases Market: Application movement analysis & market share 2024 & 2030
  • Fig. 29 Addison's Disease market, 2018 - 2030 (USD Million)
  • Fig. 30 Ankylosing Spondylitis market, 2018 - 2030 (USD Million)
  • Fig. 31 Alopecia Areata market, 2018 - 2030 (USD Million)
  • Fig. 32 Rheumatoid Arthritis market, 2018 - 2030 (USD Million)
  • Fig. 33 Systemic Lupus Erythematosus market, 2018 - 2030 (USD Million)
  • Fig. 34 Systemic Sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 35 Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 36 Antiphospholipid Antibody Syndrome market, 2018 - 2030 (USD Million)
  • Fig. 37 Diabetes Type 1 market, 2018 - 2030 (USD Million)
  • Fig. 38 Crohn's Disease market, 2018 - 2030 (USD Million)
  • Fig. 39 Ulcerative Colitis market, 2018 - 2030 (USD Million)
  • Fig. 40 Narcolepsy market, 2018 - 2030 (USD Million)
  • Fig. 41 Multiple Sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 42 Uveitis market, 2018 - 2030 (USD Million)
  • Fig. 43 Others market, 2018 - 2030 (USD Million)
  • Fig. 44 Strategy Mapping market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-287-7

U.S. IVD And LDT For Autoimmune Diseases Market Growth & Trends:

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.88 billion by 2030, growing at a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights:

  • The IVD segment gained a major market share in 2024 and is expected to grow at a CAGR of 6.26% over the forecast period, attributed to its efficient testing for both systemic & organ-specific autoimmune pathologies and better reimbursement policies.
  • Psoriasis held the largest share of 15.21% in 2024 and is expected to maintain a dominant share throughout the forecast period. The rise in psoriasis prevalence and the strategic initiatives undertaken by the NPF to improve diagnostic accuracy are key factors contributing to the segment's growth.
  • The clinical chemistry segment held the largest revenue share of 30.32% in 2024. Clinical chemistry tests play a central role in testing and diagnosing various diseases in patients.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objective
    • 1.9.1. Objective 1
    • 1.9.2. Objective2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Technology Segment Snapshot
  • 2.3. Application Segment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Emerging chronic diseases patients
      • 3.2.1.2. Increasing number of new FDA injectable generics drugs approvals
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of injectable
  • 3.3. SWOT Analysis, by Factor
  • 3.4. Industry Analysis- Porter's
  • 3.5. Consumer Behavior Analysis
  • 3.6. Target Disease Population
  • 3.7. Regulatory Scenario
  • 3.8. Reimbursement Scenario
  • 3.9. Unmet Needs and Opportunity Analysis

Chapter 4. Type Business Analysis

  • 4.1. U.S. IVD & LDT For Autoimmune Diseases Market: Type Movement Analysis
  • 4.2. IVD
    • 4.2.1. IVD Market, 2018 - 2030 (USD Million)
    • 4.2.2. By Technology
      • 4.2.2.1. Immunoassays
        • 4.2.2.1.1. Immunoassays Market, 2018 - 2030 (USD Million)
      • 4.2.2.2. Clinical Chemistry
        • 4.2.2.2.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
      • 4.2.2.3. Hematology
        • 4.2.2.3.1. Hematology Market, 2018 - 2030 (USD Million)
      • 4.2.2.4. Coagulation
        • 4.2.2.4.1. Coagulation Market, 2018 - 2030 (USD Million)
      • 4.2.2.5. Microbiology
        • 4.2.2.5.1. Microbiology Market, 2018 - 2030 (USD Million)
      • 4.2.2.6. Molecular Diagnostics
        • 4.2.2.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
      • 4.2.2.7. Others
        • 4.2.2.7.1. Others Market, 2018 - 2030 (USD Million)
    • 4.2.3. By Application
      • 4.2.3.1. Addison's Disease
        • 4.2.3.1.1. Addison's Disease Market, 2018 - 2030 (USD Million)
      • 4.2.3.2. Ankylosing Spondylitis
        • 4.2.3.2.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.3. Alopecia Areata
        • 4.2.3.3.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
      • 4.2.3.4. Rheumatoid Arthritis
        • 4.2.3.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
      • 4.2.3.5. Systemic Lupus Erythematosus
        • 4.2.3.5.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
      • 4.2.3.6. Systemic Sclerosis
        • 4.2.3.6.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.2.3.7. Psoriasis
        • 4.2.3.7.1. Psoriasis Market, 2018 - 2030 (USD Million)
      • 4.2.3.8. Antiphospholipid Antibody Syndrome
        • 4.2.3.8.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
      • 4.2.3.9. Diabetes Type 1
        • 4.2.3.9.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
      • 4.2.3.10. Crohn's Disease
        • 4.2.3.10.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
      • 4.2.3.11. Ulcerative Colitis
        • 4.2.3.11.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.12. Narcolepsy
        • 4.2.3.12.1. Narcolepsy Market, 2018 - 2030 (USD Million)
      • 4.2.3.13. Multiple Sclerosis
        • 4.2.3.13.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.2.3.14. Uveitis
        • 4.2.3.14.1. Uveitis Market, 2018 - 2030 (USD Million)
      • 4.2.3.15. Others
        • 4.2.3.15.1. Others Market, 2018 - 2030 (USD Million)
  • 4.3. LDT
    • 4.3.1. LDT Market, 2018 - 2030 (USD Million)
    • 4.3.2. By Technology
      • 4.3.2.1. Immunoassays
        • 4.3.2.1.1. Immunoassays Market, 2018 - 2030 (USD Million)
      • 4.3.2.2. Clinical Chemistry
        • 4.3.2.2.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
      • 4.3.2.3. Hematology
        • 4.3.2.3.1. Hematology Market, 2018 - 2030 (USD Million)
      • 4.3.2.4. Coagulation
        • 4.3.2.4.1. Coagulation Market, 2018 - 2030 (USD Million)
      • 4.3.2.5. Microbiology
        • 4.3.2.5.1. Microbiology Market, 2018 - 2030 (USD Million)
      • 4.3.2.6. Molecular Diagnostics
        • 4.3.2.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
      • 4.3.2.7. Others
        • 4.3.2.7.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.3. By Application
      • 4.3.3.1. Addison's Disease
        • 4.3.3.1.1. Addison's Disease Market, 2018 - 2030 (USD Million)
      • 4.3.3.2. Ankylosing Spondylitis
        • 4.3.3.2.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.3. Alopecia Areata
        • 4.3.3.3.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
      • 4.3.3.4. Rheumatoid Arthritis
        • 4.3.3.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
      • 4.3.3.5. Systemic Lupus Erythematosus
        • 4.3.3.5.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
      • 4.3.3.6. Systemic Sclerosis
        • 4.3.3.6.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.3.3.7. Psoriasis
        • 4.3.3.7.1. Psoriasis Market, 2018 - 2030 (USD Million)
      • 4.3.3.8. Antiphospholipid Antibody Syndrome
        • 4.3.3.8.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
      • 4.3.3.9. Diabetes Type 1
        • 4.3.3.9.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
      • 4.3.3.10. Crohn's Disease
        • 4.3.3.10.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
      • 4.3.3.11. Ulcerative Colitis
        • 4.3.3.11.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.12. Narcolepsy
        • 4.3.3.12.1. Narcolepsy Market, 2018 - 2030 (USD Million)
      • 4.3.3.13. Multiple Sclerosis
        • 4.3.3.13.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
      • 4.3.3.14. Uveitis
        • 4.3.3.14.1. Uveitis Market, 2018 - 2030 (USD Million)
      • 4.3.3.15. Others
        • 4.3.3.15.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. U.S. IVD & LDT For Autoimmune Diseases Market: Technology Movement Analysis
  • 5.2. Immunoassays
    • 5.2.1. Immunoassays Market, 2018 - 2030 (USD Million)
  • 5.3. Clinical Chemistry
    • 5.3.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2018 - 2030 (USD Million)
  • 5.5. Coagulation
    • 5.5.1. Coagulation Market, 2018 - 2030 (USD Million)
  • 5.6. Microbiology
    • 5.6.1. Microbiology Market, 2018 - 2030 (USD Million)
  • 5.7. Molecular Diagnostics
    • 5.7.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. U.S. IVD & LDT For Autoimmune Diseases Market: Application Movement Analysis
  • 6.2. Addison's Disease
    • 6.2.1. Addison's Disease Market, 2018 - 2030 (USD Million)
  • 6.3. Ankylosing Spondylitis
    • 6.3.1. Ankylosing Spondylitis Market, 2018 - 2030 (USD Million)
  • 6.4. Alopecia Areata
    • 6.4.1. Alopecia Areata Market, 2018 - 2030 (USD Million)
  • 6.5. Rheumatoid Arthritis
    • 6.5.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.6. Systemic Lupus Erythematosus
    • 6.6.1. Systemic Lupus Erythematosus Market, 2018 - 2030 (USD Million)
  • 6.7. Systemic Sclerosis
    • 6.7.1. Systemic Sclerosis Market, 2018 - 2030 (USD Million)
  • 6.8. Psoriasis
    • 6.8.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 6.9. Antiphospholipid Antibody Syndrome
    • 6.9.1. Antiphospholipid Antibody Syndrome Market, 2018 - 2030 (USD Million)
  • 6.10. Diabetes Type 1
    • 6.10.1. Diabetes Type 1 Market, 2018 - 2030 (USD Million)
  • 6.11. Crohn's Disease
    • 6.11.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
  • 6.12. Ulcerative Colitis
    • 6.12.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)
  • 6.13. Narcolepsy
    • 6.13.1. Narcolepsy Market, 2018 - 2030 (USD Million)
  • 6.14. Multiple Sclerosis
    • 6.14.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
  • 6.15. Uveitis
    • 6.15.1. Uveitis Market, 2018 - 2030 (USD Million)
  • 6.16. Others
    • 6.16.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
    • 7.2.1. New Product Launch
    • 7.2.2. Partnership & Collaboration
    • 7.2.3. Merger and Acquisition
    • 7.2.4. Others
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. Adaptive Biotechnologies Corporation
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Agilent Technologies, Inc
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Bio-Rad Laboratories, Inc.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. bioMerieux, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Corgenix, Inc. (Sebia)
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. F. Hoffmann-La Roche Ltd.
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Quest Diagnostics, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. PerkinElmer, Inc
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott Laboratories
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Thermo Fisher Scientific, Inc.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives